BCTXZ — BriaCell Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1610820 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -12,579,234 | -12,320,370 | 23,579,729 | 9,852,435 | 8,020,587 |
| Apr 2026 | 0 | — | -7,620,794 | -7,164,507 | 27,071,310 | 6,880,221 | 3,662,350 |
| Jan 2026 | 0 | — | -7,531,266 | -7,221,820 | 33,594,454 | 29,903,628 | 3,380,646 |
| Oct 2025 | 0 | — | -8,322,943 | -8,197,565 | 13,075,050 | 2,714,012 | 3,724,646 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,651,323
Investing CF
$-3,805,049
Financing CF
$31,814,999
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-146,659,826
Inventory
—
Receivables
$669,173
ST Investments
$10,688,277
EBIT TTM
$-35,574,649
Pretax Income TTM
$-35,325,292
Interest Exp TTM
$66,610
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | -36,054,237 | -34,904,262 | 23,579,729 | 8,020,587 | 16,400,887 | -28,651,323 |
| Jul 2024 | 0 | -33,330,076 | -4,791,466 | 5,872,261 | 8,557,193 | -2,382,410 | -24,126,128 |
| Jul 2023 | 0 | -23,272,264 | -20,302,394 | 27,163,577 | 30,940,758 | -3,777,181 | -23,744,860 |
| Jul 2022 | 0 | -15,285,553 | -26,838,903 | 42,577,041 | 32,248,109 | 10,328,932 | -12,484,376 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$27,071,310
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
2026-11-06 14:00 · Yahoo
BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough
2026-11-05 13:00 · Yahoo
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
2026-11-03 14:00 · Yahoo
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
2026-10-23 11:30 · Yahoo
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
2026-10-06 11:30 · Yahoo
BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone
2026-08-24 12:47 · Yahoo
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
2026-08-24 11:30 · Yahoo
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
2026-08-05 11:30 · Yahoo
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?
2026-07-18 03:15 · Yahoo
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
2026-07-16 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.